Shifting focus in the therapeutics of immunobullous disease

Shifting focus in the therapeutics of immunobullous disease

Therapeutics of autoimmune bullous disease has seen a major shift of focus from more global immunosuppression to targeted immunotherapy. Anti CD 20 monoclonal antibody Rituximab revolutionized the therapeutics of autoimmune bullous disease particularly pemphigus. Though it is still being practiced o...

Full description

Bibliographic Details
Main Authors: Abhishek De, Asad Ansari, Nidhi Sharma, Aarti Sarda
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2017-01-01
Series:Indian Journal of Dermatology
Subjects:
Biological treatment
immunobullous disease
rituximab
TNF inhibitors
Online Access:http://www.e-ijd.org/article.asp?issn=0019-5154;year=2017;volume=62;issue=3;spage=282;epage=290;aulast=De

Internet

http://www.e-ijd.org/article.asp?issn=0019-5154;year=2017;volume=62;issue=3;spage=282;epage=290;aulast=De

Similar Items